Stock screener

CADL

Conviction 80HealthcareScan · Mon, Aug 10, 2026
CADL$10.50-0.90%
ResistanceSupportVol 14
63 bars
Vol MA14 1.03M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Candel Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.candeltx.com
Price10.50
Change-0.90%
Gap-0.80%
Rel volume0.59×
Avg volume1.14M
Avg $ vol11.38M
SMA 2010.00
SMA 509.46
SMA 2006.68
Price vs 50+10.97%
Price vs 200+57.05%
MA stackbullish
50/200 cross
Supertrendup · 9.06
RSI (14)60
MACD hist0.04
MACD crossbull · 4d
Stoch %K / %D81 / 84
ADX (14)20
+DI / −DI22 / 17
RSI divergence
MACD divergence
ATR %+5.05%
ADR %5.48%
52w high10.59
52w low4.42
From 52w high-0.90%
Above 52w low+137.44%
New 52w highNo
SqueezeOn · 16d
Bollinger width14.93%
%B0.83
Donchian pos80.65%
Donchian high10.82
Donchian low9.16
AVWAP (52w high)9.99
vs AVWAP high+5.05%
AVWAP (52w low)7.26
vs AVWAP low+44.60%
OBV trendFlat
Chaikin MF (20)-0.01
Today vs 20d0.59×
Avg vol (14d)1.03M
Avg vol (20d)1.14M
Avg $ vol (20d)11.38M
Market cap768.97M
RS 3m (vs SPY)+30.25%
RS 6m (vs SPY)+86.07%
RS line new highNo
Trend template8/8
Technical rank88.8
1 week+4.22%
1 month+10.59%
3 months+25.69%
6 months+80.02%
1 year+79.71%
YTD+92.92%
P/E-20.14
P/B5.57
P/S
P/FCF-19.77
EPS-0.7200
Div yield
ROE-27.66%
ROA-18.91%
Debt/Eq0.01
Current28.05
EV/EBITDA-12.13
Gross margin
Net margin
Rev growth0.00%
EPS growth30.80%
Price target20.17
Target upside92.19%
Analyst ratingBuy
Institutional69.22%
Ent. value575.87M
Revenue31K
Net income-8.86M
Gross profit
Free cash flow-38.9M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out73.27M
Employees55
ListedTue, Jul 27, 2021
Free float42.26M
Float %77.0%
Short interest12.96M
Days to cover9.0d
Short volume60.6%
Squeeze score79 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.14 vs −$0.22
Last surprise+36.4% beat
Setup gradeA
Conviction80 / 100
Pattern quality
Tech rank88.8 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance11.09
Support8.55
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CADL

All disclosures →
No recent disclosed trades by Congress in CADL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CADL · 10 buys

InsiderSideShares
Sims Mark E.
Chief Commercial Officer · Stock Option (Right to Buy) · 2026-07-06
Grant285K
Benz Edward J. JR
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Loggia Nicoletta
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Martell Christopher
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Nabel Gary J.
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
PAPA JOSEPH C
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Manning Paul B
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Gaeta Renee
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Nguyen Diem
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K
Radhakrishnan Maha
Director · Stock Option (Right to Buy) · 2026-06-23
Grant32K

SEC filings

EDGAR filings in CADL · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.